Free Trial
NASDAQ:MGNX

MacroGenics (MGNX) Stock Price, News & Analysis

MacroGenics logo
$1.38 +0.12 (+9.52%)
Closing price 04:00 PM Eastern
Extended Trading
$1.36 -0.02 (-1.45%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About MacroGenics Stock (NASDAQ:MGNX)

Key Stats

Today's Range
$1.26
$1.41
50-Day Range
$1.19
$1.79
52-Week Range
$0.99
$5.77
Volume
835,878 shs
Average Volume
844,445 shs
Market Capitalization
$87.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.71
Consensus Rating
Hold

Company Overview

MacroGenics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
83rd Percentile Overall Score

MGNX MarketRank™: 

MacroGenics scored higher than 83% of companies evaluated by MarketBeat, and ranked 202nd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MacroGenics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 7 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    MacroGenics has only been the subject of 3 research reports in the past 90 days.

  • Read more about MacroGenics' stock forecast and price target.
  • Earnings Growth

    Earnings for MacroGenics are expected to decrease in the coming year, from ($1.06) to ($2.06) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MacroGenics is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MacroGenics is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    MacroGenics has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about MacroGenics' valuation and earnings.
  • Percentage of Shares Shorted

    9.54% of the float of MacroGenics has been sold short.
  • Short Interest Ratio / Days to Cover

    MacroGenics has a short interest ratio ("days to cover") of 4.8.
  • Change versus previous month

    Short interest in MacroGenics has recently decreased by 9.64%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    MacroGenics does not currently pay a dividend.

  • Dividend Growth

    MacroGenics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.54% of the float of MacroGenics has been sold short.
  • Short Interest Ratio / Days to Cover

    MacroGenics has a short interest ratio ("days to cover") of 4.8.
  • Change versus previous month

    Short interest in MacroGenics has recently decreased by 9.64%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    MacroGenics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for MacroGenics this week, compared to 6 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added MacroGenics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MacroGenics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.00% of the stock of MacroGenics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    96.89% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about MacroGenics' insider trading history.
Receive MGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.

MGNX Stock News Headlines

MacroGenics (NASDAQ:MGNX) Cut to "Sell" at Wall Street Zen
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
MacroGenics: Working On That Road To Recovery
See More Headlines

MGNX Stock Analysis - Frequently Asked Questions

MacroGenics' stock was trading at $3.25 at the beginning of the year. Since then, MGNX shares have decreased by 57.5% and is now trading at $1.38.
View the best growth stocks for 2025 here
.

MacroGenics, Inc. (NASDAQ:MGNX) posted its earnings results on Tuesday, May, 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by $0.04. The biopharmaceutical company had revenue of $13.19 million for the quarter, compared to analyst estimates of $9.59 million. MacroGenics had a negative net margin of 36.23% and a negative trailing twelve-month return on equity of 59.84%.

Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MacroGenics investors own include NVIDIA (NVDA), Broadcom (AVGO), Invesco QQQ (QQQ), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and Jabil (JBL).

Company Calendar

Last Earnings
5/13/2025
Today
7/02/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MGNX
Employees
430
Year Founded
2000

Price Target and Rating

Average Stock Price Target
$5.71
High Stock Price Target
$14.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+312.6%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$66.97 million
Pretax Margin
-35.62%

Debt

Sales & Book Value

Annual Sales
$149.96 million
Price / Cash Flow
N/A
Book Value
$1.85 per share
Price / Book
0.75

Miscellaneous

Free Float
54,888,000
Market Cap
$87.38 million
Optionable
Optionable
Beta
1.59

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:MGNX) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners